Hepatobiliary surgeons meet immunologists : the case of colorectal liver metastases patients by M. Donadon et al.
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2019;8(4):370-377 | http://dx.doi.org/10.21037/hbsn.2019.03.06
Introduction
Colorectal cancer (CRC) is the third most common cancer 
and the second most common cause of cancer-related 
deaths worldwide (1). Since the liver is the main filter 
of the venous drainage of the bowel, most patients with 
CRC develop colorectal liver metastases (CLM). Hepatic 
resection for CLM combined with systemic therapy has 
the potential to be curative for patients with CLM, as 
this therapeutic approach has been associated with 5- and 
10-year survival rates up to 50% and 35%, respectively (2). 
Indeed, fluoropyrimidine-based combinations (FOLFOX 
and FOLFIRI) with or without biological therapies using 
anti-vascular endothelial growth factor (VEGF) or anti-
epidermal growth factor receptor (EGFR) inhibitors have 
changed the natural history of CLM (3). This combined 
approach offers to a significant proportion of patients, 
who would not have been considered for surgery until a 
few years ago, the possibility to undergo hepatic resection. 
However, failure of this contemporary management is 
not uncommon, and in this case, prolonged survival is 
unusual (4,5).
In the last years, the field of cancer immunology has 
caught the attention of surgical and medical oncologists, as 
immune-based anticancer strategies, including checkpoint 
inhibitors, have been applied to different clinical scenarios 
with promising results (6-8). Anti-PD-1 or anti-PD-L1 
blocking antibodies have been used in CRC patients 
(6,9). However, significant results have been shown 
only in those patients with microsatellite instability 
(MSI), which represent up to 15% of the whole CRC 
population (10,11). Moreover, in the context of CRC in 
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particular, a careful evaluation of immune infiltrating cells 
is emerging as an important prognostic tool to classify 
cancer patients according to the features of their immune 
landscape (12,13). Thus, while we are still far from fully 
understanding the interactions between the immune system 
and cancer in CLM patients, efforts aimed at clarifying the 
oncoimmunological dynamics are expected to aid in the 
introduction of new immune-based therapeutic strategies 
and improved patient stratification. A major obstacle to 
a refined definition of the immune contexture of human 
CLM resides also in the profound heterogeneity of tumor 
lesions across patients as well as intermetastatic (12). This 
scenario is also complicated by the frequent neoadjuvant 
treatment of CLM patients; in fact, both chemotherapy and 
targeted therapy could potentially affect the type of immune 
infiltrate. From two real representative cases, in this article 
we review the immune contexture of CLM patients as 
recently discovered, illustrating the diversity of immune 
infiltrate. 
Representative case 1
A 52-year-old female was diagnosed with adenocarcinoma 
of the left colon with synchronous bilateral CLM. The 
tumor was KRAS wild-type with microsatellite stability 
(MSS). Since the primary tumor was asymptomatic, she 
was treated with FOLFOX for 6 courses with radiological 
partial response in the sigma and in the liver lesions. Then, 
she underwent multiple liver resections with the removal of 
11 histologically proven CLM. She completed 6 courses of 
FOLFOX. Finally, she underwent left colectomy. Thirteen 
months after the last surgical operation, she progressed with 
3 new CLM. She underwent 4 courses of FOLFIRI with 
cetuximab with evidence of radiological partial response. 
She underwent another liver surgery with the removal 
of the 3 CLM. Thus, she completed the second line of 
systemic therapy with another 6 courses of FOLFIRI. To 
date, she is alive and free of disease 33 months from the 
initial diagnosis. 
Figure 1  represents histological sections of the 
intratumor and peritumor areas of the resected CLM. 
Immunohistochemical staining was performed as follows: 
2 micrometer thick tissue slides from FFPE tumor sections 
were deparaffinized, and rehydrated. Antigen retrieval was 
performed using EDTA buffer (0.25 mM, pH 8) at 98 ℃ 
for 20 min, followed by block of endogenous peroxidases 
with 3% hydrogen peroxide (Sigma) and block of 
nonspecific sites with Background Sniper (Biocare Medical). 
The sections were then incubated with primary antibodies: 
CD68 (Dako, KP-1 clone, 1:1,000), CD3 (Thermo Fisher, 
SP7 clone, 1:100), and NKp46 (Abcam, polyclonal, 1:300), 
followed by incubation with detection system MACH 
1 (Biocare Medical). Sections were then incubated with 
DAB (Biocare Medical), counterstained with hematoxylin, 
dehydrated and mounted. As shown, there was a very high 
density of tumor infiltrating T and NK cells, as shown by 
the immunohistochemical staining of CD3+ and NKp46+ 
cells. In the peritumor invasive margin, also a low density of 
macrophages was observed, as documented by the staining 
of CD68+ cells. 
Representative case 2
A 37-year-old male was diagnosed with adenocarcinoma 
of the right colon with synchronous bilateral CLM. The 
tumor was KRAS mutated and had MSS. The primary 
tumor was symptomatic because of bleeding, and the 
patient was treated with right colectomy. Next, he 
Figure 1 Case study 1. Immunohistochemical evaluation of CD3 (A), NKp46 (B) and CD68 (C) on CLM paraffin sections from case study 
1. Representative pictures showing high density of CD3 and NK cells and low density of macrophages. Scale bar 100 μm (A,C), 30 μm (B); 
immunohistochemical staining. CLM, colorectal liver metastases.
A B CCD3 Nkp46 CD68
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received systemic therapy with 6 courses of FOLFOX and 
bevacizumab with evidence of radiological partial response. 
He was then considered for liver surgery and treated with 
multiple liver resections to remove 8 CLM. Later on, he 
progressed on postoperative FOLFOX and bevacizumab 
because of new CLM and bilateral lung metastases. He 
then started second line systemic therapy with FOLFIRI 
and aflibercept and remained stable for 8 months. He was 
reconsidered for loco-regional therapies (liver and lung 
resections), but he progressed significantly while on waiting 
list for liver surgery. He started a third line of systemic 
therapy with regorafenib and also received trans-arterial 
radioembolisation of the liver. None of these treatments 
achieved durable results, and he died 18 months after the 
initial diagnosis.
Figure 2 shows histological sections of the intratumor and 
peritumor area of the resected CLM. Immunohistochemical 
staining was performed as previously described. In this 
case, as opposed to the previous representative case, there 
was a low density of tumor-infiltrating T and NK cells as 
evidenced by the immunohistochemical staining of CD3+ 
and NKp46+ cells. In the peritumor invasive margin, in 
contrast, a high density of macrophages was observed 
(CD68+ cells). 
These two case reports clearly depict the heterogeneity 
of the immune infiltrate in human CLM, in terms of 
density and type of cells. Notably, the myeloid component 
(i.e., macrophages) was in sharp contrast with the 
lymphocytic one, suggesting that these two immune 
populations could have opposite prognostic values. 
A comprehensive analysis of the immune contexture 
capturing both lymphoid and myeloid components would 
be more informative and possibly disclose important 
prognostic immune variables.
The immune landscape of CRC liver metastases 
patients
The immune system includes the innate and the adaptive 
components. The first component includes the response 
mediated by NK cells, macrophages and dendritic cells. 
These cells are the frontline, and they are triggered by 
bacterial products, endotoxins and pathogenic nucleic acids. 
The second component includes T and B cells that, once 
activated, provide the basis for immune-specific protection. 
Of note, these two components of the immune system work 
together, and, in fact, there is a significant overlap in the 
activation process of these cells. 
Cancer is a disease characterized by a considerable, but 
variable, number of genetic alterations and by a loss of 
normal cellular regulatory processes (14). These genetic 
alterations result in the expression of molecules that can 
activate the innate immune system, as well as neoantigens 
expressed on the surface of cancer cells that can be 
recognized by T cells. These mechanisms are the theoretical 
premises for an effective host antitumor immune response. 
However, unfortunately tumors are able to conceive escape 
strategies to elude immune control. 
The liver is an organ endowed with peculiar immunological 
properties. Under normal conditions, a human adult liver 
contains 1010 lymphocytes, the majority of these cells 
being cytotoxic T and NK cells (14-16). Indeed, elevated 
local levels of chemokines, such as CCL5, CCL2 and IL-8 
promote leucocyte migration and accumulation in the 
hepatic parenchyma (17,18). A large amount of data available 
in the literature advocates that the infiltrating leucocytes 
have a major effect on the clinical outcome of patients with 
liver metastases (12,16-24). The tissue microenvironment 
of the metastatic liver is, in fact, characterized by increased 
Figure 2 Case study 2. Immunohistochemical evaluation of CD3 (A), NKp46 (B) and CD68 (C) on CLM paraffin sections from case study 2. 
Representative pictures showing low density of CD3 and NK cells and high density of macrophages. Scale bar 100 μm (A,C), 30 μm (B); 
immunohistochemical staining. CLM, colorectal liver metastases.
A B CCD3 Nkp46 CD68
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levels of inflammatory cytokines and perturbations of 
chemokine expression. The molecular cross talk among 
tumor-infiltrating immune cells, local tissue-resident 
immune cell populations, stromal cells and malignant 
cells determines the fate of the metastatic disease (25). 
This increased local inflammation may upset the normal 
hepatic immune cell repertoire and disrupt tumor immune 
surveillance (26). Hence, understanding the mechanisms 
inducing the infiltration of immune cells in the CLM is 
of paramount importance both for the estimation of the 
prognosis and for the development of novel and more 
effective therapies. In general, tumor-infiltrating immune 
cells have been associated with prolonged survival in 
patients with colon cancer (12,13,19,27-31). Mlecnik 
et al. (24) demonstrated a stronger association between T 
cell infiltration and prognosis in CRC over the traditional 
TNM staging system. However, most of the patients cannot 
orchestrate an effective immune response against cancer 
cells, making the comprehension of this phenomenon 
very complex. Moreover, the high heterogeneity of the 
clinical presentation of CLM, which is responsible for 
the wide array of responsiveness to treatments, could rely 
on the individual immune response. In a following work, 
the same group investigated the prognostic relevance of 
T cell infiltration in CLM and confirmed that response 
to treatment and prolonged survival of metastatic CRC 
patients were statistically significantly associated with high 
densities of immune cells (12). In addition to this, Donadon 
et al. (32) have recently evaluated the clinical relevance 
of the immune microenvironment in CLM patients, 
showing that intratumor T and NK cells were independent 
prognostic factors favoring overall survival after resection 
of CLM. Again, these prognostic factors were found to be 
much more informative than the TNM staging system and 
than many other traditional clinico-pathological factors 
that are used in clinical practice to stratify the prognosis of 
CLM patients. 
Figure 3 shows a representative cartoon of a CLM 
lesion highlighting the abundance of immune cells that 
may be found in the peritumor area. Each of the cells 
represents an element potentially contributing to the 
clinical heterogeneity of CLM patients, and could represent 
a useful tool for the development of new biomarkers and 
hence new personalized immunotherapies. 
Spatial distribution of immune cells in cancer is highly 
variable (33). The geometry of the spatial disposition 
of cancer cells, stromal cells, vessels, normal cells and 
immune cells is emerging as one of the key factors of the 
analyses. The density of the multiple types of immune cells 
infiltrating tumor tissues might be just one of the important 
features to consider when assessing the relevance of immune 
cells in cancer, and research in the field should develop a 
multiplex tool that takes into account the morphology, the 
functional characterization and the spatial arrangement 
of immune cells in cancer. Fruitful interactions among 
different immune cells might also have a prognostic value. 
For instance, the colocalization of T cells and neutrophils in 
a specific area in CRC patients was found to be associated 
with a better outcome (34). The spatial layout is even more 
important in the case of metastases, since the development 
of the metastatic niche requires multiple complex events. 
Celià-Terrassa et al. (35) recently showed how a multi-step 
process (anchorage, survival, protection and proliferation) is 
required to build a metastasis-receptive microenvironment. 
Along these lines, tumor-immune interplay is of paramount 
importance. The recruitment of immunosuppressive cells is, 
in fact, one of the first events in the process leading to the 
formation of the metastatic niche. Alternatively activated 
macrophages, neutrophils and myeloid-derived suppressor 
cells have been shown to suppress T cell infiltration and 
activation, thus promoting metastases (36,37). 
Notably, there are also strong associations between 
angiogenesis and immune cells. VEGF plays a key role 
in angiogenesis, a highly complex process that is essential 
for tumor growth. Studies have shown that VEGF has 
a significant prognostic role by affecting the metastatic 
potential of tumors and by correlating with responses to 
Kupffer cell
Monocyte
Macrophage
T cell
NK cell
Figure 3 The Immune contexture in CLM. Representative 
cartoon of a CLM lesion, showing myeloid cells (monocytes, 
macrophages), T cells, and NK cells at the tumor invasive margin. 
Kuppffer cells in the liver parenchyma are also present. CLM, 
colorectal liver metastases.
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treatment and survival (38,39). Two signaling pathways play 
important roles in the growth and metastatic potential of 
human CRCs, including the VEGF and EGFR pathways. 
EGF is one of the natural ligands of the EGFR, which 
is a transmembrane tyrosine kinase receptor critical for 
normal cell proliferation and differentiation. An increased 
level of EGFR seems to be an important factor driving 
the aggressive behavior of cancer cells (40). Many studies 
have shown a relationship between high EGFR levels and 
high-grade tumors and poor prognosis (41). In line with 
this, some experimental data has shown that inhibition of 
the EGFR pathway is associated with increased immune 
infiltration in solid cancers (42). In this regard, it has 
also been reported that blocking the EGFR signaling 
pathway facilitates the activation of immune cells and their 
recruitment to tumor sites via the production of several 
cytokines and chemokines (42). This is particularly relevant 
for NK cells, as studies have shown that the use of a 
blocking anti-EGFR monoclonal antibody stimulates these 
innate immune effector lymphocytes and induces antibody-
dependent cell cytotoxicity. At the same time, the refractory 
effect of the tumor against this biological compound may 
be explained by the induction of mechanisms enacted by the 
tumor to evade immune responses. 
Among the different immune cells, tumor-associated 
macrophages (TAMs) deserve special attention. Macrophages 
are widely distributed in the body, and function both as 
inflammatory cells, engaged in recognition, ingestion, 
and degradation of cellular debris, foreign material, and 
pathogens, as well as tissue resident cells, by contributing to 
maintaining homeostasis in tissues. (43). This is also the case 
of the resident macrophages of the liver, Kupffer cells (KCs), 
found lining the walls of the sinusoids. KCs are crucial for 
clearing the blood entering the sinusoids from pathogens and 
dangerous endogenous compounds, and are also endowed 
with high scavenger ability, important for their role in 
iron recycling from senescent red blood cells (44). Due to 
their surveillance functions, liver resident macrophages 
have a tolerogenic and immunosuppressive phenotype 
in homeostasis. On the other hand, liver macrophages 
also hold a central and important role during both acute 
and chronic liver injuries. The heterogeneity in the liver 
macrophage population relies also on one of the most 
important shifting paradigms about the origin of hepatic 
macrophages (44). In fact, it has long been assumed that 
tissue macrophages originate from circulating monocytes, 
but it is now increasingly clear that some tissue resident 
macrophages, including KCs, are long-lived and self-
renewing cells, able to persist independently from the 
embryo into adulthood (45). Therefore, considering that 
the liver harbors approximately 80% of the macrophages 
in the whole body, and is anyway patrolled by blood 
monocytes, liver macrophages represent a promising target 
for innovative therapies in liver diseases (46). In a recent 
work, Grossmann et al. showed that targeting of CCR2+ 
inflammatory monocytes differentiating to intratumor 
macrophages resulted in restored anti-tumor immunity 
and increased overall survival in a preclinical model of 
metastatic CRC (47). This result is sharply in contrast 
to the positive prognostic function of TAMs in CLM 
documented in human studies and suggests that the scenario 
is very complex (48). Such discrepancies could arise from 
the different monocyte subsets considered. Distinct subsets 
of monocytes can differentiate in intrahepatic macrophages, 
giving rise to TAMs with protumor or antitumor functions. 
For instance, circulating intermediate monocytes (CD14++/
CD16+) have been shown to contribute to the response to 
chemotherapy and antiangiogenic cancer treatment (49).
To date, limited data is available on the role of TAMs 
in CLM patients. The density of TAMs correlates with 
survival in primary liver tumor, such as hepatocellular 
carcinoma (50) and in colo-rectal liver metastases (48). In this 
work, in particular, a higher density of TAMs at the invasive 
margin was associated with a better outcome for CLM 
patients, both as longer disease-free survival and overall 
survival. Both TAM density and TAM-related markers (e.g., 
CD68) have been found to correlate with patient prognosis 
(51,52). Similar data has been recently proposed for patients 
with cholangiocarcinoma (53). Interestingly, TAMs may 
express PDL-1, thus acting as immune-suppressor agents, 
suggesting that they could contribute to the mechanism of 
action of immunotherapies with anti-PD1 or PDL-1 (54). 
Therefore, the density of TAMs could be used as a surrogate 
of therapeutic effects of such immunotherapy. It is commonly 
known that TAMs are highly plastic and integrate multiple 
signals to shape their response (55). In the injured liver, 
macrophages can rapidly change their phenotype depending 
on the hepatic microenvironment (56). Thus, an imbalance 
between subtypes of TAMs, for instance M2-type versus 
M1-type in cancer patients, should be seen as an important 
element of study in cancer research. The identification 
of microenvironmental factors and corresponding 
transcriptional networks underlying macrophage polarization 
might lead to novel therapeutic strategies. Reshaping of 
macrophage functions and polarization has, in fact, been 
suggested in different ways. For instance, Liu et al. (57) 
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showed that silica nanoparticles could trigger the release 
of cytokines that could polarize macrophages towards 
an M1-like phenotype. The modulation of macrophage 
differentiation and in particular the restoration from M2-
like to M1-like could be an effective way to control the 
immune microenvironment in CLM patients. Taken 
together, the progress in understanding macrophage 
heterogeneity in liver diseases, and in CLM patients, 
strongly suggest that we will soon be able to translate these 
findings into novel therapies in clinical practice. 
Key elements also emerge from the genetics of the 
disease. In a large cohort of colorectal tumors, a gene-gene 
correlation network was built to understand which genes 
might be associated with the anti-tumor response (58). 
Many different genes were identified, but interestingly, 
most of them were linked to the host immune functionality 
(T and B cell activation, inflammatory response, T and B 
cell differentiation, adhesion- and migration-associated 
chemokines and activation of NK cells), which convincingly 
suggest that the immune system deserves further attention. 
Consistent with this, Pitroda et al. (59) recently reported 
an elegant classification on 134 consecutive resections 
for CLM that integrated three molecular subtypes 
matched with the clinical risk stratification. The most 
favorable subtype was the so-called immune type, which 
corresponded to those metastases with a high density of 
CD3+ and CD8+ cells in the peritumor and intratumor 
compartments with minimal fibrosis. These CLM were 
associated with some specific mutations, such as POLE, 
ARID2, EBF1 and CDK12, which were found predictive 
of the cytotoxic immune response (60). Taken together, 
the current knowledge suggests that the identification of 
favorable and unfavorable subtypes of CLM patients, both 
for genetic mutations and for complex alterations of the 
tumor microenvironment, is one of the ways to provide the 
most effective and customizable therapeutic options that 
might be associated with durable survival. This data and 
results support how the host immune system represents an 
emerging hallmark of cancer, which should not be left to 
exploratory translational research anymore, while it should 
be routinely considered in clinical practice. However, this 
data gives the idea that we are still far from the decoding 
the immune landscape of CLM patients. 
Conclusions
Understanding the interactions between immune and 
cancer cells in CLM in general, and in individual CLM 
patients, should be a priority in cancer research. The 
final endpoint is to unearth the basics in order to design 
approaches arming the immune system against cancer, 
with the aim to achieve durable survival after surgery and 
systemic therapy. Many variables can act as confounding 
factors in the analyses, and many others can hinder the 
battle conducted by the immune system. Such research 
should be conducted in synergy between hepatobiliary 
surgeons, medical oncologists and immunologists to offer 
an individualized approach, which will likely allow decoding 
the clinical, pathological, biological and immunological 
intrigue of CLM patients. 
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